Literature DB >> 11063816

Cryptococcal glucuronoxylomannan delays translocation of leukocytes across the blood-brain barrier in an animal model of acute bacterial meningitis.

M M Lipovsky1, L Tsenova, F E Coenjaerts, G Kaplan, R Cherniak, A I Hoepelman.   

Abstract

In bacterial meningitis, neurological damage is associated with a high influx of polymorphonuclear leukocytes (PMN) into the brain. Previous data suggest that the capsular component of the fungus C. neoformans, glucuronoxylomannan (GXM), interferes with PMN-migration into the cerebrospinal fluid (CSF). Therefore, a rabbit model of bacterial meningitis was treated intravenously with GXM. This resulted in (1) a reduction of PMN in the CSF at 6 h (P=0.05), (2) reduced peak TNF-alpha concentrations in the CSF, and (3) diminished tissue inflammation and intravascular margination of PMN in GXM-treated animals. Thus, GXM may represent a novel adjuvant anti-inflammatory agent in bacterial meningitis.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11063816     DOI： 10.1016/s0165-5728(00)00354-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  13 in total

Review 1.  Reprogramming the host response in bacterial meningitis: how best to improve outcome?

Authors:  M van der Flier; S P M Geelen; J L L Kimpen; I M Hoepelman; E I Tuomanen
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 2.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

3.  Phenotypic switching of Cryptococcus neoformans can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitis.

Authors:  B C Fries; S C Lee; R Kennan; W Zhao; A Casadevall; D L Goldman
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

Review 4.  How Environmental Fungi Cause a Range of Clinical Outcomes in Susceptible Hosts.

Authors:  Steven T Denham; Morgan A Wambaugh; Jessica C S Brown
Journal:  J Mol Biol       Date:  2019-05-09       Impact factor: 5.469

5.  Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis.

Authors:  Luciana Tissi; Manuela Puliti; Francesco Bistoni; Paolo Mosci; Thomas R Kozel; Anna Vecchiarelli
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Utility of a novel lipoarabinomannan assay for the diagnosis of tuberculous meningitis in a resource-poor high-HIV prevalence setting.

Authors:  Vinod B Patel; Ahmed I Bhigjee; Hoosain F Paruk; Ravesh Singh; Richard Meldau; Cathy Connolly; Thumbi Ndung'u; Keertan Dheda
Journal:  Cerebrospinal Fluid Res       Date:  2009-11-02

Review 7.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

8.  Cryptococcal glucuronoxylomannan inhibits adhesion of neutrophils to stimulated endothelium in vitro by affecting both neutrophils and endothelial cells.

Authors:  Pauline M Ellerbroek; Andy I M Hoepelman; Floor Wolbers; Jaap Jan Zwaginga; Frank E J Coenjaerts
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

9.  Comparison of a clinical prediction rule and a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence setting.

Authors:  Vinod B Patel; Ravesh Singh; Cathy Connolly; Victoria Kasprowicz; Allimudin Zumla; Thumbi Ndungu; Keertan Dheda
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

10.  Multiple Disguises for the Same Party: The Concepts of Morphogenesis and Phenotypic Variations in Cryptococcus neoformans.

Authors:  Oscar Zaragoza
Journal:  Front Microbiol       Date:  2011-09-06       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.